Web-based portal may improve quality of adverse event reports
This article was originally published in The Silver Sheet
FDA and the National Institutes of Health have entered into a memorandum of understanding that aims to deliver a centralized Web-based portal for adverse event reporting that may improve report quality, lower costs and reduce delivery time. Both agencies already are working on their own revamped adverse event reporting systems. FDA has its long-term sights on a single, agency-wide electronic portal - dubbed MedWatch Plus - for collecting adverse events, consumer complaints and other information relating to all products it regulates. NIH has created the Federal Adverse Event Task Force (of which FDA is a part) to develop a portal designed so clinical trial adverse events can be reported in a single, standardized format. With the MOU, the agencies are combining efforts. "NIH and FDA aim to develop a project that will result in a Web-based method for consumers, health professionals, investigators, sponsors and other parties to electronically submit [adverse event] reports," the memorandum states
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.